ConductScience.org, home

Comparison · NCT00489736-8ed9497e

Dronedarone 400mg Bid vs Amiodarone 600mg/200mg od: Treatment Failure

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Dronedarone 400mg Bid vs Amiodarone 600mg/200mg od: Treatment Failure. Trial comparisons, record NCT00489736-8ed9497e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00489736-8ed9497e

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.7390.6810.79wilson
Risk in group 20.5530.4920.613wilson
Risk difference, group 1 minus group 20.1860.1030.266newcombe hybrid score
Risk ratio, group 1 over group 21.341.171.53log
Odds ratio, group 1 over group 22.291.573.33log
Number needed to treat, for one more participant with the outcome on Dronedarone 400mg Bid than on Amiodarone 600mg/200mg od5.383.779.73from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Dronedarone 400mg Biddronedarone tablets 400mg twice daily (bid)184249OG000
Group 2Amiodarone 600mg/200mg odamiodarone 600mg once daily (od) for 28 days, then amiodarone 200mg once daily (od)141255OG001

Outcome

Type
PRIMARY
Title
Treatment Failure
Description
The primary event is the treatment failure defined as the first recurrence of atrial fibrillation or premature study drug discontinuation for intolerance or lack of efficacy according to the investigator judgement. The primary efficacy analysis is performed on the time from first study drug intake to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.
Time frame
minimum study duration is 6 months (+10 days); maximum is 15 months
Population
All randomized and treated patients (receiving at least one dose of study drug) were included in the efficacy analysis according to the treatment received.

Source ClinicalTrials.gov

Trial

Title
Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
NCT number
NCT00489736
Phases
PHASE3
Conditions
Atrial Fibrillation
Interventions
dronedarone (SR33589), amiodarone
Lead sponsor
Sanofi
Results first posted
2009-11-09

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00489736-8ed9497e